Abstract
The need for optimal treatment of the active forms of multiple sclerosis (MS), especially highly active MS (HAMS), poses a number of difficult problems for specialists, including not only the choice of a highly effective disease-modifying drug for MS (DMDMS), but also conditions for the timely and safe switching from other DMDMS. A group of expert neurologists from various clinics in Russia presents a consensus on the practical aspects of switching patients with HAMS from other DMDMS to cladribine tablets, which has been registered in Russia in March 2020. The paper discusses indications for changing therapy and gives indications, contraindications, and conditions for initiating cladribine therapy. It details the procedure and results of the expert consensus, on the basis of which the recommendations have been developed to switch to cladribine tablets from each of the DMDMS registered in Russia for the treatment of MS.
Highlights
Сиверцева С.А.13, Соколова А.А.14, 15, Спирин Н.Н.10, Хабиров Ф.А.16, 17, Парадника Д.18 1ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад
A group of expert neurologists from various clinics in Russia presents a consensus on the practical aspects of switching patients with highly active MS (HAMS) from other disease-modifying drug for MS (DMDMS) to cladribine tablets, which has been registered in Russia in March 2020
The paper discusses indications for changing therapy and gives indications, contraindications, and conditions for initiating cladribine therapy. It details the procedure and results of the expert consensus, on the basis of which the recommendations have been developed to switch to cladribine tablets from each of the DMDMS registered in Russia for the treatment of multiple sclerosis (MS)
Summary
*Нарастание >1,5 балла, если исходная EDSS = 0; любое нарастание EDSS при исходном значении EDSS >5,5 расцениваются как «более значимый» параметр; **наличие более чем одного очага в спинном мозге расценивается как «более значимый» параметр.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
